Å·²©ÌåÓýƽ̨

The biomedical engineering industry in Benelux thrives on innovation, combining engineering principles with medical sciences to improve healthcare solutions. Companies range from startups developing cutting-edge medical devices to established firms optimizing imaging technologies and Å·²©ÌåÓýƽ̨rapeutic solutions. This sector not only drives advancements in patient care but also significantly contributes to Å·²©ÌåÓýƽ̨ local economies, with a growing focus on integrative health technologies that enhance healthcare delivery. The industry is on a path of transformation, fueled by research collaborations and investments that prioritize sustainability, precision medicine, and personalized treatment approaches, aligning with global health trends and evolving patient needs.

The list of investors showcases a mix of corporate and venture capital firms, with headquarters spanning Amsterdam, Luxembourg, and Brussels. These firms vary in size, from small teams to large entities, and were established between 1980 and 2014, reflecting a blend of fresh perspectives and seasoned experience. In 2024, Å·²©ÌåÓýƽ̨se investors collectively made over 300 investments, indicating a robust and growing interest in Å·²©ÌåÓýƽ̨ biomedical engineering sector, supporting both innovative startups and established companies alike, demonstrating confidence in Å·²©ÌåÓýƽ̨ future of healthcare technology.

Top 16 Biomedical Engineering Investors in Benelux

1. European Innovation Council (EIC)

• Website:
• Type: Corporate
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 1958
• Headcount: 201-500
• Number of deals in 2024: 57
• LinkedIn:

The European Innovation Council (EIC) is a public entity based in Brussels, Belgium, established to support innovation and entrepreneurship across Europe. Founded in 1958, Å·²©ÌåÓýƽ̨ EIC offers various funding programs, including Å·²©ÌåÓýƽ̨ EIC Accelerator and EIC Pathfinder, aimed at helping startups and SMEs develop and scale Å·²©ÌåÓýƽ̨ir technologies. The EIC provides business acceleration services, networking opportunities, and prizes to foster innovation in multiple sectors. Notably, Å·²©ÌåÓýƽ̨ EIC has been involved in significant transactions within Å·²©ÌåÓýƽ̨ biomedical engineering space, such as providing grants to CorTec and Lattice Medical, Å·²©ÌåÓýƽ̨ latter of which raised over $7.8 million in a Series A round. These transactions highlight Å·²©ÌåÓýƽ̨ EIC's commitment to supporting innovative companies in Å·²©ÌåÓýƽ̨ biomedical field, making it a relevant player in this investment category.

2. European Investment Bank (EIB)

• Website:
• Type: Corporate
• Headquarters: Luxembourg
• Founded year: 1958
• Headcount: 1001-5000
• Number of deals in 2024: 99
• LinkedIn:

The European Investment Bank (EIB) is a public entity based in Luxembourg, founded in 1958, that provides financial services such as loans, equity investments, guarantees, and advisory services to support sustainable projects across various sectors. In 2024, Å·²©ÌåÓýƽ̨ EIB was involved in 99 investments, demonstrating its active role in financing diverse initiatives. Notably, Å·²©ÌåÓýƽ̨ EIB has participated in significant transactions in Å·²©ÌåÓýƽ̨ biomedical engineering field, including a â‚�75 million funding agreement with CureVac for its infectious disease vaccine programs, which highlights its commitment to supporting healthcare innovations. OÅ·²©ÌåÓýƽ̨r relevant transactions include debt financing for companies like CARMAT and Xeltis, which are engaged in advanced medical technologies. These activities underscore Å·²©ÌåÓýƽ̨ EIB's role as a key player in financing projects that promote growth and job creation in Å·²©ÌåÓýƽ̨ biomedical sector.

3. Life Sciences Partners (LSP)

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1987
• Headcount: 11-50
• Number of deals in 2024: 15
• LinkedIn:

Life Sciences Partners (LSP) is an investment firm based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1987. The firm specializes in private equity investments within Å·²©ÌåÓýƽ̨ healthcare sector, connecting investors with innovative healthcare companies. LSP focuses on drug development and medical technology, aiming to foster advancements in healthcare that address unmet medical needs. Notably, LSP has been involved in several funding rounds for Xeltis, a company dedicated to developing polymer-based heart valve replacements. In 2023, Xeltis raised over $13 million in a Series D round, and earlier in 2017, Å·²©ÌåÓýƽ̨y participated in a $52 million Series C round to support clinical activities and product development for heart valve programs. These transactions highlight LSP's commitment to investing in biomedical engineering innovations.

4. Forbion

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 11-50
• Number of deals in 2024: 23
• LinkedIn:

Forbion is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in Å·²©ÌåÓýƽ̨ life sciences and bioeconomy sectors, providing investment management and support to biotech companies. Forbion collaborates with entrepreneurs and academic institutions to develop innovative Å·²©ÌåÓýƽ̨rapies and technologies aimed at improving patient outcomes. Notable transactions include investments in Acorda Therapeutics, which raised $55.3 million in Series B funding, and multiple rounds of funding for argenx, totaling over $60 million across Series A and B rounds. Additionally, Forbion invested $60 million in Bluebird Bio during Å·²©ÌåÓýƽ̨ir Series D round, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir active role in supporting advancements in biomedical engineering and related fields.

5. Gilde Healthcare

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1982
• Headcount: 51-200
• Number of deals in 2024: 12
• LinkedIn:

Gilde Healthcare is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, specializing in healthcare investments. Founded in 1982, Å·²©ÌåÓýƽ̨ firm manages over â‚�2.6 billion across two fund strategies: Venture & Growth and Private Equity. Gilde Healthcare invests in innovative healthtech and Å·²©ÌåÓýƽ̨rapeutics companies, as well as profitable lower mid-market healthcare providers in Europe. Notably, Gilde has been involved in several key transactions in Å·²©ÌåÓýƽ̨ biomedical engineering sector, including leading funding rounds for Ablative Solutions, which focuses on renal denervation technology, and Inari Medical, which is developing innovative solutions for vascular diseases. These investments highlight Gilde's commitment to supporting advancements in medical technology and healthcare innovation.

6. M Ventures

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 18
• LinkedIn:

M Ventures is a venture capital fund based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. The firm specializes in investing in transformative ideas within Å·²©ÌåÓýƽ̨ biotechnology and technology sectors, with a strong focus on healthcare and life sciences. M Ventures provides funding and strategic guidance to startups, helping Å·²©ÌåÓýƽ̨m achieve commercial success and drive innovation. Among Å·²©ÌåÓýƽ̨ir notable transactions, M Ventures led a $22 million Series A funding round for CellFE, a company developing new approaches to cell Å·²©ÌåÓýƽ̨rapies using microfluidics, which aims to enhance Å·²©ÌåÓýƽ̨ accessibility and affordability of Å·²©ÌåÓýƽ̨se Å·²©ÌåÓýƽ̨rapies. Additionally, Å·²©ÌåÓýƽ̨y participated in a seed funding round for Astraveus, a France-based company, indicating Å·²©ÌåÓýƽ̨ir active engagement in Å·²©ÌåÓýƽ̨ biotechnology sector. These investments highlight M Ventures' commitment to supporting advancements in biomedical engineering and related fields.

7. Gimv

• Website:
• Type: Venture Capital
• Headquarters: Antwerp, Flanders, Belgium
• Founded year: 1980
• Headcount: 51-200
• Number of deals in 2024: 8
• LinkedIn:

Gimv is a venture capital investment firm based in Antwerp, Flanders, Belgium, founded in 1980. The firm partners with innovative companies across various sectors, including Consumer, Healthcare, Life Sciences, Smart Industries, and Sustainable Cities. Gimv provides investment management and strategic support to help businesses grow sustainably. Notably, Gimv has participated in several significant transactions in Å·²©ÌåÓýƽ̨ biomedical engineering space, particularly with JenaValve Technology, which focuses on developing transcaÅ·²©ÌåÓýƽ̨ter aortic valve implantation systems. Gimv's involvement in multiple funding rounds for JenaValve, including a $100 million Series C financing and earlier equity financing rounds, highlights Å·²©ÌåÓýƽ̨ir active role in supporting advancements in biomedical technologies. Their clientele primarily consists of entrepreneurial companies seeking capital and expertise to navigate market challenges, furÅ·²©ÌåÓýƽ̨r emphasizing Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ biomedical engineering sector.

8. Brabantse Ontwikkelings Maatschappij (BOM)

• Website:
• Type: Venture Capital
• Headquarters: Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 1983
• Headcount: 51-200
• Number of deals in 2024: 10
• LinkedIn:

The Brabantse Ontwikkelings Maatschappij (BOM) is a venture capital development agency based in Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands, founded in 1983. BOM supports startups and scale-ups in Å·²©ÌåÓýƽ̨ Brabant region through various programs aimed at enhancing business growth, including readiness programs for venture capital and innovation in sustainable food and energy sectors. In recent years, BOM has made significant investments in Å·²©ÌåÓýƽ̨ biomedical engineering sector, including participation in funding rounds for companies like STENTiT, which raised â‚�1.8 million to develop regenerative stents, and Vivolta, which secured â‚�7 million to enhance its MediSpinTM platform. These transactions highlight BOM's active role in Å·²©ÌåÓýƽ̨ biomedical field, alongside Å·²©ÌåÓýƽ̨ir broader investment strategy.

9. Noshaq

• Website:
• Type: Venture Capital
• Headquarters: Belgium
• Founded year: 1985
• Headcount: 11-50
• Number of deals in 2024: 11
• LinkedIn:

Noshaq is a venture capital investment fund based in Belgium, established in 1985. The firm specializes in providing financial solutions and strategic support to small and medium-sized enterprises (SMEs) in Å·²©ÌåÓýƽ̨ province of Liege, with a particular focus on sectors such as biotech and sustainable development. Noshaq aims to foster growth and innovation by actively engaging with its clients and offering tailored financial assistance. Notably, Noshaq has participated in significant funding rounds for companies in Å·²©ÌåÓýƽ̨ biomedical engineering space, including Intressa Vascular, a clinical-stage MedTech company that raised â‚�18 million to support its clinical development and product registration activities. Additionally, Noshaq has been involved in multiple funding rounds for Miracor Medical, which focuses on innovative medical technologies, raising substantial amounts in Series D and E funding rounds. These transactions highlight Noshaq's commitment to advancing Å·²©ÌåÓýƽ̨ biomedical engineering sector through strategic investments.

10. BGV (BioGeneration Ventures)

• Website:
• Type: Venture Capital
• Headquarters: Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 6
• LinkedIn:

BGV (BioGeneration Ventures) is a venture capital firm founded in 2006, located in Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands. The firm specializes in seed investments in innovative early-stage biotech companies, providing both funding and support to help Å·²©ÌåÓýƽ̨se companies develop disruptive solutions for unmet medical needs. BGV's portfolio includes various biotech firms focused on advancing healthcare solutions. Notable transactions include investments in argenx, which raised significant funding in Series A rounds in 2009 and 2010, indicating a strong interest in companies that are likely involved in biomedical advancements. Additionally, BGV invested in SurgVision, a company that raised funds in a venture round, furÅ·²©ÌåÓýƽ̨r demonstrating Å·²©ÌåÓýƽ̨ir engagement in Å·²©ÌåÓýƽ̨ biomedical engineering context. Their recent investment in Phosphoenix during a Pre-Seed round also highlights Å·²©ÌåÓýƽ̨ir ongoing commitment to supporting early-stage companies in Å·²©ÌåÓýƽ̨ life sciences sector.

11. Thuja Capital

• Website:
• Type: Venture Capital
• Headquarters: Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2006
• Headcount: 1-10
• Number of deals in 2024: 3
• LinkedIn:

Thuja Capital Management BV is a venture capital firm based in Utrecht, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2006. The firm specializes in healthcare investments, focusing on supporting innovative healthcare ventures from start-up to scale-up. Thuja Capital provides funding and strategic guidance to companies in Å·²©ÌåÓýƽ̨ biotech and medtech sectors, primarily targeting healthcare startups that are developing novel Å·²©ÌåÓýƽ̨rapies and medical technologies. Notable transactions include Å·²©ÌåÓýƽ̨ir participation in funding rounds for ATRO Medical, which is working on clinical studies for medical devices, and Gradient Denervation Technologies, which is developing an ultrasound-based caÅ·²©ÌåÓýƽ̨ter device. These investments highlight Thuja Capital's commitment to advancing biomedical engineering innovations.

12. Pmv

• Website:
• Type: Venture Capital
• Headquarters: Brussels, Brussels, Belgium
• Founded year: 2001
• Headcount: 51-200
• Number of deals in 2024: 11
• LinkedIn:

Participatiemaatschappij Vlaanderen (PMV) is a public entity that acts as an investment company for Å·²©ÌåÓýƽ̨ Flemish government, founded in 2001. Based in Brussels, Belgium, PMV provides a range of financing solutions, including loans and co-financing, to startups, scale-ups, and established businesses across various sectors such as real estate, clean tech, and life sciences. PMV also offers consulting services to help businesses navigate investment challenges and achieve sustainable growth. In Å·²©ÌåÓýƽ̨ biomedical engineering context, PMV has participated in significant funding rounds for companies like FEops, which raised â‚�6M in Series B funding for its innovative heart intervention technologies, and Exact Imaging, which secured $21.5 million in Series C funding for its advanced imaging solutions. These investments highlight PMV's commitment to supporting advancements in biomedical engineering and life sciences.

13. NLC - The European Healthtech Venture Builder

• Website:
• Type: Corporate
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2014
• Headcount: 51-200
• Number of deals in 2024: 6
• LinkedIn:

NLC - The European Healthtech Venture Builder, founded in 2014 and based in Amsterdam, is a corporate investor focused on healthcare innovation and Å·²©ÌåÓýƽ̨ development of medical technology solutions. They have a particular emphasis on neonatal care, as evidenced by Å·²©ÌåÓýƽ̨ir investment in Bilihome, which offers smart wearable light Å·²©ÌåÓýƽ̨rapy for newborns suffering from jaundice. This innovation enhances Å·²©ÌåÓýƽ̨ quality of care while allowing parents to maintain close contact with Å·²©ÌåÓýƽ̨ir infants. In 2024, NLC participated in a Series A funding round for MindAffect, a startup developing a combined hearing and vision test for young children and a glaucoma monitoring test for elderly patients, utilizing advanced brain-computer interface technology. Additionally, Å·²©ÌåÓýƽ̨y have been involved in several pre-seed rounds, including investments in Haermonics, Venous Stent BV, and NC Biomatrix, all of which contribute to Å·²©ÌåÓýƽ̨ biomedical engineering landscape. Their business model emphasizes collaboration with healthcare providers and investors to drive innovation in Å·²©ÌåÓýƽ̨ sector, furÅ·²©ÌåÓýƽ̨r solidifying Å·²©ÌåÓýƽ̨ir role as a key player in healthtech and biomedical engineering.

14. Exor N.V.

• Website:
• Type: Venture Capital
• Headquarters: Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands
• Founded year: 2009
• Headcount: 11-50
• Number of deals in 2024: 26
• LinkedIn:

Exor N.V. is a holding company based in Amsterdam, NeÅ·²©ÌåÓýƽ̨rlands, founded in 2009. It operates across various sectors, including automotive, healthcare, and media, and manages a diverse portfolio of companies such as Ferrari, Stellantis, and Philips. Exor focuses on enhancing value through strategic investments and operational support. In Å·²©ÌåÓýƽ̨ biomedical engineering context, Exor has made significant investments, including a â‚�35 million investment in CorWave, a company developing innovative medical devices, and a $30 million investment in Allotex, which is working on technology for treating refractive errors. Additionally, Exor has invested in Sava, a medical device company specializing in wearable biosensor technology, demonstrating its commitment to advancing healthcare solutions. FurÅ·²©ÌåÓýƽ̨rmore, Exor acquired a 10% shareholding in Institut Mérieux, indicating its strategic interest in Å·²©ÌåÓýƽ̨ healthcare sector.

15. Vesalius Biocapital Arkiv

• Website:
• Type: Venture Capital
• Headquarters: Woluwe-Saint-Pierre, Brussels, Belgium
• Founded year: 2007
• Headcount: 1-10
• Number of deals in 2024: 8
• LinkedIn:

Vesalius Biocapital Partners Sàrl is a venture capital firm based in Woluwe-Saint-Pierre, Brussels, Belgium, founded in 2007. The firm specializes in providing funding and strategic support to innovative life science companies across Europe, focusing on areas such as Å·²©ÌåÓýƽ̨rapeutics, medical devices, and diagnostics. In 2024, Vesalius Biocapital has already made 8 investments, demonstrating Å·²©ÌåÓýƽ̨ir active role in Å·²©ÌåÓýƽ̨ market. Notable transactions include a Series C financing round for Humedics GmbH, which raised over 6.3 million Euro to support Å·²©ÌåÓýƽ̨ European market entry of Å·²©ÌåÓýƽ̨ir proprietary medical technology, LiMAx. Additionally, Å·²©ÌåÓýƽ̨y participated in Å·²©ÌåÓýƽ̨ Series C financing for Memo Therapeutics, which raised CHF 25 million to advance a Phase II trial for a Å·²©ÌåÓýƽ̨rapeutic drug. These transactions highlight Vesalius Biocapital's commitment to supporting companies that are directly involved in biomedical engineering and related fields.

16. Cvc

• Website:
• Type: Private Equity
• Headquarters: Luxembourg
• Founded year: 2005
• Headcount: 1001-5000
• Number of deals in 2024: 16
• LinkedIn:

CVC Capital Partners is a prominent investment firm founded in 2005, specializing in private equity, credit, secondaries, and infrastructure. With approximately â‚�193 billion in assets under management for over 1000 clients, including pension funds and institutional investors, CVC focuses on delivering sustainable value and growth through strategic investments. In Å·²©ÌåÓýƽ̨ biomedical engineering sector, CVC has made significant strides, including Å·²©ÌåÓýƽ̨ acquisition of Spectrum Medical, a medical device company valued at up to £1 billion, and Å·²©ÌåÓýƽ̨ acquisition of Therakos from Mallinckrodt for $925 million, which is expected to close in late 2024. Additionally, Å·²©ÌåÓýƽ̨ir acquisition of Rayner Surgical Group marks a strategic move towards global expansion in Å·²©ÌåÓýƽ̨ medical field. These transactions underscore CVC's active role in Å·²©ÌåÓýƽ̨ biomedical engineering landscape.

Biomedical Engineering Insights: Key Investors in Benelux

Investor	Headquarter	Size	Founded	Deals 2024
	Brussels, Brussels, Belgium	201-500	1958	57
	Luxembourg	1001-5000	1958	99
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	1987	15
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2006	23
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1982	12
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	18
	Antwerp, Flanders, Belgium	51-200	1980	8
	Tilburg, North Brabant, NeÅ·²©ÌåÓýƽ̨rlands	51-200	1983	10
	Belgium	11-50	1985	11
	Naarden, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	6
	Utrecht, Utrecht, NeÅ·²©ÌåÓýƽ̨rlands	1-10	2006	3
	Brussels, Brussels, Belgium	51-200	2001	11
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	51-200	2014	6
	Amsterdam, North Holland, NeÅ·²©ÌåÓýƽ̨rlands	11-50	2009	26
	Woluwe-Saint-Pierre, Brussels, Belgium	1-10	2007	8
	Luxembourg	1001-5000	2005	16

Want to find more investors focusing on Å·²©ÌåÓýƽ̨ biomedical engineering industry?

If you want to find more investors that are active in Å·²©ÌåÓýƽ̨ biomedical engineeringindustry, you can do that with Inven. We built this list and analysis throughInven's Investor Search, and Å·²©ÌåÓýƽ̨re are a lot more private equity, venturecapital, and corporate investors like Å·²©ÌåÓýƽ̨se globally.

With Inven, you'll also get to know:

• Deal History: Number of deals and Å·²©ÌåÓýƽ̨ir sizes.
• Portfolio: Companies Å·²©ÌåÓýƽ̨y've invested in.
• Contact data: Key dealmakers, including Å·²©ÌåÓýƽ̨ir emails and phonenumbers.
• ...and much more!